Drug delivery implants in the treatment of vitreous inflammation

Jillian Wang, Angela Jiang, Malav Joshi, John B Christoforidis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article.

Original languageEnglish (US)
Article number780634
JournalMediators of Inflammation
Volume2013
DOIs
StatePublished - 2013

Fingerprint

Drug Implants
Triamcinolone Acetonide
Drug Delivery Systems
Polymers
Fluocinolone Acetonide
Inflammation
Office Visits
Ganciclovir
Liposomes
Nanoparticles
Dexamethasone
Clinical Trials
Pathology
Equipment and Supplies
Therapeutics
Infection
Pharmaceutical Preparations
Ranibizumab

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Drug delivery implants in the treatment of vitreous inflammation. / Wang, Jillian; Jiang, Angela; Joshi, Malav; Christoforidis, John B.

In: Mediators of Inflammation, Vol. 2013, 780634, 2013.

Research output: Contribution to journalArticle

@article{eeb077ec5dcc431c9fb0ff24926b7d49,
title = "Drug delivery implants in the treatment of vitreous inflammation",
abstract = "The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article.",
author = "Jillian Wang and Angela Jiang and Malav Joshi and Christoforidis, {John B}",
year = "2013",
doi = "10.1155/2013/780634",
language = "English (US)",
volume = "2013",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Drug delivery implants in the treatment of vitreous inflammation

AU - Wang, Jillian

AU - Jiang, Angela

AU - Joshi, Malav

AU - Christoforidis, John B

PY - 2013

Y1 - 2013

N2 - The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article.

AB - The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article.

UR - http://www.scopus.com/inward/record.url?scp=84885571516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885571516&partnerID=8YFLogxK

U2 - 10.1155/2013/780634

DO - 10.1155/2013/780634

M3 - Article

C2 - 24191132

AN - SCOPUS:84885571516

VL - 2013

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 780634

ER -